Edeniq Withdraws Countersuit, Turns to Recovering its Attorneys’ Fees
After its recent success in defeating all claims in the lawsuit filed by Aemetis, Inc. (NASDAQ:AMTX), Edeniq, Inc. today
announced that it has voluntarily withdrawn its cross-claims. Edeniq had brought this countersuit to assist it in defending against
Aemetis’ meritless case; having now achieved that clear victory, Edeniq has chosen not to incur the time and expense of a trial.
Edeniq will now turn to recovering the attorneys’ fees and costs it believes it is entitled to pursuant to the parties’ terminated
merger agreement.
“By defeating every one of Aemetis’ claims, Edeniq has fully achieved its goals in this litigation. We look forward to putting
this lawsuit behind us and continuing to focus on our industry, our investors, and especially our customers,” stated Brian Thome,
President and CEO of Edeniq.
About Edeniq, Inc.
Edeniq, Inc. is a leading biotechnology company that develops processes for producing and measuring cellulosic ethanol from corn
kernel fiber through its Intellulose technology. Edeniq’s Intellulose requires zero capital investment and is easily integrated
into existing ethanol production facilities. Edeniq was established in 2008 and is headquartered in Visalia, Calif. with a field
office in Omaha, Neb. More information can be found at
www.edeniq.com.
Lily Wachter
lwachter@edeniq.com
559-302-1777
View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005791/en/